Evaluation of multiple transcriptomic gene risk signatures in male breast cancer
Abstract Male breast cancer (BCa) is a rare disease accounting for less than 1% of all breast cancers and 1% of all cancers in males. The clinical management is largely extrapolated from female BCa. Several multigene assays are increasingly used to guide clinical treatment decisions in female BCa, h...
Guardado en:
Autores principales: | Jane Bayani, Coralie Poncet, Cheryl Crozier, Anouk Neven, Tammy Piper, Carrie Cunningham, Monika Sobol, Stefan Aebi, Kim Benstead, Oliver Bogler, Lissandra Dal Lago, Judith Fraser, Florentine Hilbers, Ingrid Hedenfalk, Larissa Korde, Barbro Linderholm, John Martens, Lavinia Middleton, Melissa Murray, Catherine Kelly, Cecilia Nilsson, Monika Nowaczyk, Stephanie Peeters, Aleksandra Peric, Peggy Porter, Carolien Schröder, Isabel T. Rubio, Kathryn J. Ruddy, Christi van Asperen, Danielle Van Den Weyngaert, Carolien van Deurzen, Elise van Leeuwen-Stok, Joanna Vermeij, Eric Winer, Sharon H. Giordano, Fatima Cardoso, John M. S. Bartlett |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/39b74ac02205476a9300ff36cbb33d6d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Exome sequencing of germline DNA from non-BRCA1/2 familial breast cancer cases selected on the basis of aCGH tumor profiling.
por: Florentine S Hilbers, et al.
Publicado: (2013) -
A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer
por: Inge van denBerg, et al.
Publicado: (2021) -
Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancer
por: Tesa M. Severson, et al.
Publicado: (2018) -
Liraglutide for Weight Management in the Real World: Significant Weight Loss Even if the Maximal Daily Dose Is Not Achieved
por: Liesbet Trenson, et al.
Publicado: (2021) -
Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
por: Anna E. M. Bastiaansen, et al.
Publicado: (2020)